Compare WLDN & MGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WLDN | MGTX |
|---|---|---|
| Founded | 1964 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Military/Government/Technical | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.1B |
| IPO Year | 2006 | 2018 |
| Metric | WLDN | MGTX |
|---|---|---|
| Price | $67.85 | $11.71 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 7 |
| Target Price | ★ $114.50 | $24.57 |
| AVG Volume (30 Days) | 257.7K | ★ 801.1K |
| Earning Date | 05-07-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 120.89 | 33.02 |
| EPS | ★ 0.55 | N/A |
| Revenue | ★ $273,352,000.00 | $81,391,000.00 |
| Revenue This Year | N/A | $141.38 |
| Revenue Next Year | $12.05 | N/A |
| P/E Ratio | $127.55 | ★ N/A |
| Revenue Growth | N/A | ★ 144.57 |
| 52 Week Low | $64.67 | $6.62 |
| 52 Week High | $137.00 | $15.35 |
| Indicator | WLDN | MGTX |
|---|---|---|
| Relative Strength Index (RSI) | 28.21 | 44.09 |
| Support Level | $64.67 | $8.84 |
| Resistance Level | $85.06 | $11.85 |
| Average True Range (ATR) | 2.73 | 0.65 |
| MACD | 0.08 | -0.24 |
| Stochastic Oscillator | 5.20 | 3.45 |
Willdan Group Inc is a provider of professional technical and consulting services to utilities, private industry, and public agencies at all levels of government. It operates in the business segments of Energy and Engineering and Consulting. It generates the majority of its revenue from the Energy segment, which includes services such as audit and surveys, program design, master planning, benchmarking analysis, design engineering, construction management, performance contracting, installation, advances in software and data analytics, and other services. All of its revenue is derived from the domestic markets.
MeiraGTx Holdings PLC is a vertically integrated, clinical-stage genetic medicines company focused on developing targeted therapies for diseases with high unmet need, including radiation-induced xerostomia, Parkinson's disease, and AIPL1-associated retinal dystrophy. The company's pipeline is supported by end-to-end in-house manufacturing capabilities, including GMP viral vector production, plasmid manufacturing, and quality control, enabling development from IND to commercial supply. It also utilizes proprietary platforms in viral vector optimization and riboswitch-based gene regulation to enhance efficacy and reduce dosage. The company operates in the United States, the United Kingdom, and the European Union.